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The role of a1 and a5 subunit-containing GABAA receptors
in motor impairment induced by benzodiazepines in rats
Marija Milic´a, Jovana Divljakovic´a, Sundari Rallapallib, Michael L. van Linnb,
Tamara Timic´a, James M. Cookb and Miroslav M. Savic´a
Benzodiazepines negatively affect motor coordination and
balance and produce myorelaxation. The aim of the present
study was to examine the extent to which populations of
c-aminobutyric acid A (GABAA) receptors containing a1 and
a5 subunits contribute to these motor-impairing effects in
rats. We used the nonselective agonist diazepam and
the a1-selective agonist zolpidem, as well as nonselective,
a1-subunit and a5-subunit-selective antagonists flumazenil,
bCCt, and XLi093, respectively. Ataxia and muscle
relaxation were assessed by rotarod and grip strength
tests performed 20min after intraperitoneal treatment.
Diazepam (2mg/kg) induced significant ataxia and
muscle relaxation, which were completely prevented by
pretreatment with flumazenil (10mg/kg) and bCCt (20mg/kg).
XLi093 antagonized the myorelaxant, but not the ataxic
actions of diazepam. All three doses of zolpidem (1, 2, and
5mg/kg) produced ataxia, but only the highest dose
(5mg/kg) significantly decreased the grip strength.
These effects of zolpidem were reversed by bCCt at
doses of 5 and 10mg/kg, respectively. The present
study demonstrates that a1 GABAA receptors mediate
ataxia and indirectly contribute to myorelaxation
in rats, whereas a5 GABAA receptors contribute
significantly, although not dominantly, to muscle
relaxation but not ataxia. Behavioural Pharmacology
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Introduction
Benzodiazepines (BZs) were introduced into clinical
practice in the beginning of the 1960s and, since then,
have been widely prescribed as anxiolytic, hypnotic, anti-
convulsant, and myorelaxant drugs. During the 1990s, it
became clear that the pharmacological effects of BZs are
mediated by positive modulation of four different subtypes
of g-aminobutyric acid A (GABAA) receptors, namely those
containing the a1, a2, a3, or a5 subunit, in addition to the
g2 subunit (Sieghart, 2006). Genetic and pharmacological
studies, by the means of the generation of mutant mouse
lines [a1(H101R), a2(H101R), a3(H126R), and a5(H105R)
knock-ins] (Rudolph and Mo¨hler, 2004) and synthesis of
novel, subtype-selective ligands, have helped in linking
particular behavioral responses to specific GABAA receptor
subtypes. The sedative effects of BZs were principally
attributed to the a1-GABAA receptor subtype, anxiolytic
actions to a2/a3 containing receptors, anterograde amnesic
effects to a1/a5 subtypes, and anticonvulsant activity
partially to a1-GABAA receptors (Lo¨w et al., 2000; McKernan
et al., 2000; Collinson et al., 2002; Savic´ et al., 2009).
BZs negatively affect motor coordination and balance,
that is, they induce ataxia, which is, together with
myorelaxation, often referred to as motor impairment
(Verster et al., 2002; Licata et al., 2009). In contrast to
ataxia, myorelaxation can be therapeutically desirable,
and disentangling the molecular substrates of these two
effects would benefit the development of compounds
with an improved pharmacological profile. Like sedation,
the impaired coordination and balance were also ascribed
to potentiation at a1-GABAA receptors and these results
were consistent with experiments in both rodents and
nonhuman primates (McKernan et al., 2000; Platt et al.,
2002; Licata et al., 2009). Ligands that lack or have
substantially decreased activity at a1-GABAA receptors,
compared with conventional nonselective BZs, did not
engender ataxia over the wide dose range tested (Licata
et al., 2005; Mirza et al., 2008; Savic´ et al., 2008; Atack
2010). The experiments on genetically modified mice
have excluded the role of the a1 subunit as a molecu-
lar substrate of myorelaxation (Rudolph et al., 1999;
McKernan et al., 2000) and found that the myorelaxant
properties of diazepam are mainly mediated by a2-GABAA
receptors; at very high doses of diazepam, the a3-GABAA
and a5-GABAA receptor subtypes may also become
implicated (Crestani et al., 2001). However, a number of
pharmacological studies have shown that muscle relaxa-
tion induced by nonselective BZ-site agonists could be
reversed with the use of the a1-GABAA selective
antagonist b CCt, demonstrating ambiguity in this area
(Griebel et al., 1999; Licata et al., 2009).
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The overall aim of the present study was to examine, by
pharmacological means, the extent to which a1-GABAA
and a5-GABAA receptor subtypes contribute to BZ-
induced ataxia and muscle relaxation in Wistar rats and
to provide further information on the molecular sub-
strates of these two effects. Benzodiazepine-induced
ataxia in rodents is usually measured using the rotarod
test (Mirza et al., 2008; Savic´ et al., 2008), whereas the
myorelaxant effects of BZs are often assessed using the
grip strength test (Maurissen et al., 2003). In the present
study, we used diazepam, a ligand with high efficacy and
no selectivity for GABAA receptor subtypes, and the
a1-GABAA receptor-selective agonist zolpidem, which
possesses intermediate and no affinity for a2/a3-GABAA
and a5-GABAA receptor subtypes, respectively (Sanna
et al., 2002). Using the GABAA nonselective antagonist
flumazenil, the a1-subunit affinity-selective antagonist
bCCt (Shannon et al., 1984), and the a5-subunit affinity-
selective and efficacy-selective antagonist XLi093 (Li
et al., 2003), we examined the degree to which zolpidem-




Male Wistar rats, weighing 200–230 g, were supplied by
Military Farm, Belgrade, Serbia. Rats were housed in groups
of six and were maintained under standard laboratory
conditions (21±21C, relative humidity 40–45%) with free
access to pellet food and tap water. They were kept on
a 12 : 12h light/dark cycle with lights on at 07.00h.
All handling and testing took place during the light
phase of the diurnal cycle. Experiments were carried out
in accordance with the European Economic Community
Directive 86/609 and were approved by the Ethical
Committee on Animal Experimentation of the Faculty of
Pharmacy in Belgrade.
Rotarod test
Motor performance was assessed using an automated
rotarod (Ugo Basile, Comerio, Italy). Before testing, rats
were trained for 3 days until they could remain on a
revolving rod for 120 s with acceleration from 15 rpm to
25 rpm. During the training days, all animals were given
three training sessions of 2min each, with a 30min
intersession interval. On the fourth day, rats that met
the given criteria were selected for inclusion in the
experiment. Groups of 6–8 animals received one of
the following treatments: diazepam (0 and 2mg/kg) in
combination with bCCt (0, 1, 5, 20, and 30mg/kg),
flumazenil (0, 10, and 20mg/kg), or XLi093 (0, 10, and
20mg/kg), as well as zolpidem (0, 1, 2, and 5mg/kg) and
zolpidem (0 and 2mg/kg) combined with bCCt (0, 5, and
20mg/kg) or flumazenil (0, 10, and 20mg/kg). Latency to
falling off the rod was recorded automatically for each
animal.
Grip strength test
This test was used to examine the myorelaxant propert-
ies of agonists, antagonists, and their combinations.
Two experiments were performed: in the first, animals
received diazepam (0 and 2mg/kg) in combination with
three levels of flumazenil (0, 10, and 20mg/kg), bCCt
(0, 20, and 30mg/kg), and XLi093 (0, 10 and 20mg/kg);
in the second experiment, animals received zolpidem
(0, 1, 2, and 5mg/kg) and zolpidem (0 and 5mg/kg) in
combination with bCCt (0 and 10mg/kg). After admin-
istration of the appropriate treatment, rats were allowed
to grip, with their front paws, a metal trapezoid wire
attached to a grip-strength meter (Ugo Basile, Italy). Grip
strength was tested by dragging the rat gently by the tail.
The apparatus measured the pull force (expressed in
grams) necessary to overcome the animal’s forelimbs
grip-strength to the bar connected to a force transducer.
Each animal was given three consecutive trials and the
maximum value was taken.
Drugs
The compounds used were diazepam (Galenika, Belgrade,
Serbia), zolpidem (Toronto Chemical Research, Toronto,
Ontario, Canada), flumazenil (Feicheng BoYuan Fine
Chemicals Co. Ltd, East Feicheng, China), XLi093 (4H-
imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-ethynyl-
5,6-dihydro-5-methyl-6-oxo-, 1,3-propanediyl ester), the
a5-subunit affinity-selective and efficacy-selective an-
tagonist, and bCCt (t-butyl-b-carboline-3-carboxylate),
the a1-subunit affinity-selective antagonist; the latter two
agents were synthesized at the Department of Chemistry
and Biochemistry, University of Wisconsin–Milwaukee,
USA. The ligands were suspended in a solvent containing
85% distilled water, 14% propylene glycol, and 1% Tween-
80. All animals received two intraperitoneal injections
consisting of the appropriate ligand(s) and/or solvent (in a
total volume of 2ml/kg), 20min before the testing. When
a combination of two compounds was administered, the
first compound was injected into the lower right and the
second into the lower left quadrant of the peritoneum.
Statistics
All numerical data presented in the figures are shown as
the mean±SEM. The dose response of zolpidem was
assessed using one-way analysis of variance (ANOVA),
with a post-hoc Student–Newman–Keuls test. The effects
of combined treatments were assessed using two-way




Animals that received 2mg/kg diazepam spent signifi-
cantly less time on the rotarod than the control group of
rats (Fig. 1; P<0.001). When diazepam was injected
immediately after flumazenil, a significant main effect of
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flumazenil [F(2,40)=18.07, P<0.001] and diazepam
flumazenil interaction [F(2,45)=18.07, P<0.001] were
found. Both 10 and 20mg/kg of flumazenil antagonized
the motor incoordination induced by diazepam (Fig. 1a;
both P<0.001 compared with 2mg/kg diazepam).
Similarly, coadministration of bCCt resulted in a sig-
nificant treatment effect [F(4,68)=4.05, P<0.005]
and a significant diazepam bCCt interaction [F(4,77)=
3.83, P<0.01]. Although the two lower doses of bCCt (1
and 5mg/kg) failed to antagonize the diazepam-induced
motor impairment, coadministration of the two higher
doses of bCCt (20 and 30mg/kg) significantly increased
the time spent on the rotarod (Fig. 1b; both P<0.001),
when compared with diazepam dosed at 2mg/kg. XLi093,
an a5-selective antagonist, did not antagonize the diazepam-
induced motor incoordination (Fig. 1c).
All three doses of zolpidem (1, 2, and 5mg/kg) impaired
motor coordination (Fig. 2a; P<0.001 in all three cases).
Pretreatment with flumazenil significantly influenced the
zolpidem-induced ataxia [zolpidem: F(1,37)=114.02,
P<0.001; zolpidem flumazenil interaction: F(2,42)=
108.54, P<0.001]. When compared with animals that
received only 2mg/kg of zolpidem, animals treated with
the combination of zolpidem 2mg/kg+ flumazenil (10
or 20mg/kg) spent significantly more time on the rotarod
(Fig. 2b; P<0.001 and P<0.001, respectively). The
effect on motor coordination of bCCt [F(1,34)=73.94,
P<0.001] and the zolpidem bCCt interaction [F(2,39)=
40.61, P<0.001] was also significant. The subsequent post-
hoc test showed that both 5 and 20mg/kg of bCCt
antagonized the zolpidem-induced ataxia (Fig. 2c; both
P<0.001, compared with 2mg/kg zolpidem). There was also
a significant difference in the time spent on the rotarod be-
tween animals that received 2mg/kg zolpidem+5mg/kg
bCCt and animals that received only 5mg/kg bCCt
(P<0.025). None of the antagonists (flumazenil, bCCt,
and XLi093) itself impaired the motor performance on
the rotarod.
Grip strength
Application of 2mg/kg diazepam produced significant
muscle relaxation (Fig. 3; P<0.01, relative to control).
For the combination of diazepam+ flumazenil, two-way
ANOVA showed significant effects of diazepam [F(1,31)=
6.09, P<0.02] and the flumazenil diazepam interaction
[F(2,36)=5.94, P<0.01); coadministration of flumazenil
(10 and 20mg/kg) reversed the diazepam-induced myor-
elaxation (Fig. 3a; P<0.001 and P<0.01, compared with
diazepam 2mg/kg, respectively). As with flumazenil, the
effect of bCCt did not reach statistical significance,
whereas the effect of diazepam [F(1,28)=7.82, P<0.01]
as well as the interaction [F(2,33)=5.83, P<0.01] were
significant. There were significant differences between the
group that received 2mg/kg diazepam and groups that
received 2mg/kg diazepam with either 20 or 30mg/kg of
XCCt (Fig. 3b; P<0.05 and P<0.001, respectively). The
assessment of the results obtained with the a5-selective
antagonist showed no significant effect of XLi093 on grip
strength [F(2,30)=2.46, NS], but showed a significant
diazepamXLi093 interaction [F(2, 35)=6.18, P<0.01];
the differences between groups that received diazepam+
XLi093 (10 and 20mg/kg) and the group that received
diazepam were statistically significant (Fig. 3c; P<0.002
and P<0.005, respectively).
Zolpidem significantly decreased grip strength
[F(3,20)=10.34, P<0.001]. Muscle relaxation was
significant with 5mg/kg zolpidem (P<0.001), whereas
the two lower doses (1 and 2mg/kg) were at the control
level (Fig. 4a). When the combination 5mg/kg zolpi-


































































The influence of pretreatment with antagonists (a) flumazenil (Flu), (b) bCCt, and (c) XLi093 on diazepam-induced (Dzp) ataxia on the rotarod. Data
are mean±SEM from n=8 rats per group. ***P less than 0.001 versus vehicle; + +P less than 0.01 versus 2mg/kg diazepam; +++P less than
0.001 versus 2mg/kg diazepam.
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zolpidem [F(1,15)=19.74, P<0.001], bCCt F(1,15)=
16.11, P<0.001] and their interaction [F(1,18)=27.53,
P<0.001] were found. Although bCCt itself did not alter
grip strength, its addition to zolpidem reversed the zolpidem-
induced muscle relaxation (Fig. 4b; P<0.001, compared
with 5mg/kg zolpidem).
Discussion
Studies on genetically modified mice, in which a distinct
a subunit of GABAA receptors is rendered insensitive to
diazepam, represent valuable tools in revealing which
receptor subtype is necessary for the expression of a
specific behavioral response. These experiments pointed
toward a1-GABAA receptors as the main subtype in
eliciting ataxia in mice (McKernan et al., 2000). In the
present study, diazepam-induced and zolpidem-induced
ataxia on the rotarod in rats was successfully antagonized
with the a1-selective antagonist bCCt. Because of its
20-fold selectivity for a1-GABAA receptors compared with
a2-GABAA and a3-GABAA receptors, bCCt is one of the
most selective BZ-site ligands identified to date (Cox
et al., 1995; Huang et al., 2000). In many behavioral
studies, bCCt successfully reversed the effects of BZs
related to the a1-GABAA receptor subtype, such as ataxia,
sedation, and anticonvulsant activity (Griebel et al.,



























































(a) Effects of zolpidem (Zol) on rotarod performance and the influence of pretreatment with (b) flumazenil (Flu) and (c) bCCt on ataxia induced
by zolpidem (2mg/kg). Data are mean±SEM from n=6 rats per group. *P less than 0.05 versus vehicle; ***P less than 0.001 versus vehicle;
























































The influence of pretreatment with the antagonists (a) flumazenil (Flu), (b) bCCt, and (c) XLi093 on the diazepam-induced (Dzp) muscle relaxation
measured in the grip strength test. Data are mean±SEM from n=8 rats per group. **P less than 0.05 versus vehicle; ***P less than 0.001 versus
vehicle; +P less than 0.05 versus 2mg/kg diazepam; + +P less than 0.01 versus 2mg/kg diazepam; +++P less than 0.001 versus 2mg/kg
diazepam.
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all experiments using bCCt as the a1-selective ligand
have reported antagonism of the diazepam-induced ataxia
in mice or rats. Such discrepancies may have resulted
from differences in the experimental design. Shannon
and colleagues, (1984) reported that administration of
30mg/kg bCCt did not attenuate the diazepam-induced
ataxia in mice. The degree of motor impairment was
assessed using an inverted-screen test, where the
concomitant myorelaxation was likely to influence the
performance of the test. Another study found that motor
incoordination engendered by diazepam, triazolam, and
zolpidem in mouse pups was not sensitive to bCCt
(Rowlett et al., 2001). However, motor impairment was
related to rolling motions, as opposed to normal
locomotor activity of mouse pups, and probably involved
a predominantly spinal mechanism and engagement of
a2-GABAA and a3-GABAA receptor subtypes (McKernan
and Whiting, 1996). In the present study, the dose of
bCCt needed to antagonize zolpidem-induced ataxia was
substantially lower than the dose that antagonized the
effect of diazepam (5 vs. 20mg/kg). This implies that
an effect of diazepam, possibly myorelaxation, mediated
by receptors other than the a1-GABAA receptor, may have
contributed to the influence of diazepam, but not
zolpidem, on rotarod test performance. In this scenario,
the dose of 20mg/kg of bCCt may have either blocked
the a1-GABAA receptor population more completely or
started to prevent binding of diazepam to non-a1-GABAA
receptors.
The possibility that the a5-GABAA receptor subtype plays
a modulatory role in behavioral effects predominantly
conferred by the a1 subunit, such as sedation, tolerance
development, and memory impairment, has been pre-
viously proposed (van Rijnsoever et al., 2004; Savic´ et al.,
2008; Savic´ et al., 2009). Hence, we tested the ability of
the a5 selective antagonist XLi093 to influence the
diazepam-induced ataxia. At the dose of 20mg/kg, which
was previously shown to intensify diazepam-induced
sedation (Savic´ et al., 2009), XLi093 did not significantly
affect the motor-impairing effect of diazepam. This
means that ataxia, as assessed in the rotarod test in
rats, is not dependent on the activation of a5-GABAA
receptors.
Although genetic studies did not detect any role of the a1
subunit in mediating muscle relaxation (Rudolph et al.,
1999; McKernan et al., 2000), the data from experiments
with subtype-selective ligands varied from one study to
another depending on the species used and the dose of
agonist or antagonist applied (Griebel et al., 1999; Elliot
and White, 2001; Licata et al., 2009). In a radiotelemetric
study in rats, zolpidem at the dose of 5mg/kg, but not
2.5mg/kg, induced a significant decrease in electromyo-
graphic activity, a parameter aimed to assess muscle
relaxation (Elliot and White, 2001). In the present study,
significant myorelaxation observed after both diazepam
and zolpidem administration was prevented by pretreat-
ment with bCCt. As the dose of zolpidem producing
myorelaxation (5mg/kg) was substantially higher than the
minimal dose that induced ataxia (1mg/kg), the possibi-
lity that zolpidem-induced myorelaxation is not mediated
by a1-GABAA receptors needs to be discussed. Despite its
binding preference for a1-GABAA receptors, zolpidem
also binds to and potentiates effects at a2-GABAA and
a3-GABAA receptors (Sanna et al., 2002). The in-vivo
selectivity of zolpidem for the a1-enriched cerebellum, in
contrast to a2/a3-enriched spinal cord, assessed through
the reduction in flumazenil binding, is generally less than
the a1 selectivity of this compound in vitro (Atack et al.,
1999). However, the displacement curve for zolpidem in
the spinal cord of rats (Benavides et al., 1992) and mice
(Atack et al., 1999) is relatively flat, and very high doses of









Zol 0 Zol 1
(a) (b)















(a) Muscle-relaxant effect of zolpidem (Zol) and (b) the influence of pretreatment with bCCt. Data are mean±SEM from n=6 rats per group. **P less
than 0.05 versus vehicle; ***P less than 0.001 versus vehicle; +++P less than 0.001 versus 5mg/kg zolpidem.
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needed for half-inhibition of radio-labeled flumazenil
binding in this region predominantly implicated in GABA-
mediated myorelaxation (Bohlhalter et al., 1996). Thus,
one can conclude that muscle-relaxant effect of zolpidem
at the dose of 5mg/kg may not be exclusively mediated
by a2-GABAA receptors, the subtype largely responsible
for the muscle-relaxant effect of diazepam (Crestani et al.,
2001). In contrast, bCCt (30mg/kg) reversed diazepam-
induced muscle relaxation in mice (Griebel et al., 1999),
and at the dose of 3mg/kg, it attenuated the myorelaxant
properties of several nonselective benzodiazepine ago-
nists in squirrel monkeys (Licata et al., 2009). The
propensity of bCCt to antagonize some of the principally
non-a1-mediated effects of diazepam was also shown in
the elevated plus-maze and light-dark test of anxiety
(Griebel et al., 1999; Belzung et al., 2000). Nonetheless,
a potentiating effect of 30mg/kg bCCt on the anxiolytic
actions of BZs in rats has also been repeatedly reported
(Savic´ et al., 2004, 2005), which cannot be a consequence
of putative antagonism on a2-GABAA receptors. Assess-
ment of the ability of 10mg/kg bCCt (intraperitoneally)
to displace the radio-labeled flumazenil in mice indicates
that bCCt at the given dose level preferentially targets
the cerebellum, whereas it binds to less than 40% of
GABAA receptors, mainly of the a2-subtype, in the spinal
cord (Rowlett et al., 2005). Given the doses of zolpidem
and bCCt that we used, we hypothesize that under our
experimental conditions, the actions of these ligands may,
to a small extent, have involved the a2-GABAA receptor
subtype, in addition to the predominantly affected
a1-GABAA receptor subtype. In the presence of intense
activation of a1-GABAA receptors by a large dose of
zolpidem, the presumed small involvement of a2-GABAA
receptors may have been large enough to trigger muscle
relaxation.
The contribution of the a5 subunit in mediating the
muscle-relaxant effect of diazepam was observed in a5
(H105R) mutant mice (Crestani et al., 2002). Here, we
report on antagonism of the muscle-relaxant effect of
diazepam with the a5-selective ligand XLi093 in rats.
Nonetheless, muscle relaxation can be achieved without
the apparent activation of a5-GABAA receptors, as
demonstrated in experiments with zolpidem (Elliot and
White, 2001; Licata et al., 2009). Furthermore, an a2/a3
selective compound devoid of agonistic activity at the a5
subunit exerted muscle relaxation in monkeys (Licata
et al., 2005). These results suggest that the role of the a5
subunit in the BZ-induced myorelaxation could be
described as nondominant, but still significant, and
should be further investigated.
The present study demonstrates that a1-GABAA and
a5-GABAA receptor subtypes differentially contribute to
the motor-impairing effects of BZs in rats. Although
activation of a1-GABAA receptors is a prerequisite for
eliciting ataxia, these receptors are probably not directly
involved in mediating muscle relaxation but still may
contribute to the manifestation of this effect triggered by
a small fraction of activated a2-GABAA receptors. In
contrast, activation of a5-GABAA receptors contributes
significantly, although not dominantly, to muscle relaxa-
tion, but not ataxia. Thus, in the quest for ligands with an
improved pharmacological profile, it could be of impor-
tance to avoid substantial potentiation through a1
subunits, if ataxia is to be prevented, whereas a certain
level of activation at both a1 and a5 subunits could be
advantageous when muscle relaxation is required.
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